@IMI_JU’s @IMITransBioLine aims to discover and develop new safety biomarkers for early clinical trials—and recently made advancements in the potential implementation of new kidney, liver, vascular and CNS biomarkers. Read more from the FDA. #PFEColleague bit.ly/3t136ZO t.co/qYhOMIkH6…